Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial).


BACKGROUND Detailed pharmacokinetics to guide oseltamivir (Tamiflu®) dosing in morbidly obese patients is lacking. METHODS The OPTIMO trial was a single-centre, non-randomized, open-label pharmacokinetic study of single-dose and steady-state oral oseltamivir phosphate and its carboxylate metabolite in healthy, morbidly obese [body mass index (BMI) >  40… (More)
DOI: 10.1093/jac/dkr257

5 Figures and Tables


  • Presentations referencing similar topics